{"hands_on_practices": [{"introduction": "Differentiating mucinous from non-mucinous pancreatic cysts is a critical step in risk stratification, as mucinous neoplasms carry malignant potential. Cyst fluid carcinoembryonic antigen ($CEA$) is a widely used biomarker to aid in this distinction. This first practice problem [@problem_id:4613755] provides a foundational exercise in quantitative clinical reasoning, guiding you to calculate and interpret the core performance metrics of a diagnostic test—sensitivity, specificity, and predictive values—from raw clinical data.", "problem": "A surgical oncology service evaluates cystic lesions of the pancreas to triage patients for resection. In a prospective dataset of $300$ resected pancreatic cystic lesions, histopathology (the reference standard) established that $180$ lesions were mucinous and $120$ were non-mucinous. Preoperatively, cyst fluid carcinoembryonic antigen (CEA) was measured, and a decision threshold of $192$ ng/mL was used to indicate a mucinous cyst. The observed counts were:\n- Among histologically mucinous lesions: $126$ had cyst fluid CEA $\\geq 192$ ng/mL and $54$ had cyst fluid CEA $ 192$ ng/mL.\n- Among histologically non-mucinous lesions: $18$ had cyst fluid CEA $\\geq 192$ ng/mL and $102$ had cyst fluid CEA $ 192$ ng/mL.\n\nUsing histopathology as the gold standard and the accepted definitions of diagnostic test accuracy metrics, compute the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of cyst fluid CEA for differentiating mucinous versus non-mucinous cystic neoplasms at the $192$ ng/mL cutoff. Express each result as a decimal fraction (not a percent) and round your answers to three significant figures. Report your final answer in the order $\\big($sensitivity, specificity, PPV, NPV$\\big)$. Then, briefly interpret the clinical utility of this test for mucinous differentiation in terms of its rule-in versus rule-out performance based on these values.", "solution": "The problem is valid as it presents a well-defined question in biostatistics based on a consistent and scientifically plausible clinical dataset. All necessary information is provided, and the terminology used is standard in the field of diagnostic test evaluation.\n\nFirst, we organize the provided data into a $2 \\times 2$ contingency table. The disease condition is whether the pancreatic cystic lesion is mucinous (Disease Positive, $D+$) or non-mucinous (Disease Negative, $D-$), as determined by histopathology. The test outcome is whether the cyst fluid carcinoembryonic antigen (CEA) level is greater than or equal to $192$ ng/mL (Test Positive, $T+$) or less than $192$ ng/mL (Test Negative, $T-$).\n\nThe givens are:\n-   True Positives (TP): Number of mucinous lesions with CEA $\\geq 192$ ng/mL. $TP = 126$.\n-   False Negatives (FN): Number of mucinous lesions with CEA $ 192$ ng/mL. $FN = 54$.\n-   False Positives (FP): Number of non-mucinous lesions with CEA $\\geq 192$ ng/mL. $FP = 18$.\n-   True Negatives (TN): Number of non-mucinous lesions with CEA $ 192$ ng/mL. $TN = 102$.\n\nWe can verify the marginal totals from these counts:\n-   Total with disease (mucinous) = $TP + FN = 126 + 54 = 180$.\n-   Total without disease (non-mucinous) = $FP + TN = 18 + 102 = 120$.\n-   Total test positives = $TP + FP = 126 + 18 = 144$.\n-   Total test negatives = $FN + TN = 54 + 102 = 156$.\n-   Total population = $TP + FN + FP + TN = 126 + 54 + 18 + 102 = 300$.\n\nThe four diagnostic accuracy metrics are defined as follows:\n\n1.  **Sensitivity** is the probability of a positive test result given that the disease is present. It measures the test's ability to correctly identify those with the disease.\n    $$ \\text{Sensitivity} = \\frac{TP}{TP + FN} $$\n2.  **Specificity** is the probability of a negative test result given that the disease is absent. It measures the test's ability to correctly identify those without the disease.\n    $$ \\text{Specificity} = \\frac{TN}{TN + FP} $$\n3.  **Positive Predictive Value (PPV)** is the probability that the disease is present given a positive test result. It represents the proportion of positive test results that are true positives.\n    $$ \\text{PPV} = \\frac{TP}{TP + FP} $$\n4.  **Negative Predictive Value (NPV)** is the probability that the disease is absent given a negative test result. It represents the proportion of negative test results that are true negatives.\n    $$ \\text{NPV} = \\frac{TN}{FN + TN} $$\n\nNow, we substitute the given values into these formulas and compute the results.\n\n-   Calculation for Sensitivity:\n    $$ \\text{Sensitivity} = \\frac{126}{126 + 54} = \\frac{126}{180} = 0.7 $$\n-   Calculation for Specificity:\n    $$ \\text{Specificity} = \\frac{102}{102 + 18} = \\frac{102}{120} = 0.85 $$\n-   Calculation for Positive Predictive Value:\n    $$ \\text{PPV} = \\frac{126}{126 + 18} = \\frac{126}{144} = 0.875 $$\n-   Calculation for Negative Predictive Value:\n    $$ \\text{NPV} = \\frac{102}{54 + 102} = \\frac{102}{156} \\approx 0.653846\\dots $$\n\nThe problem requires rounding each result to three significant figures.\n-   Sensitivity = $0.700$\n-   Specificity = $0.850$\n-   PPV = $0.875$\n-   NPV $\\approx 0.654$\n\nBrief interpretation of clinical utility:\nThe performance of this test varies for ruling in versus ruling out mucinous cysts.\n-   **Rule-in Performance**: The test has a high specificity ($0.850$) and a high positive predictive value ($0.875$). High specificity indicates a low false-positive rate (only $18/120$ or $15\\%$ of non-mucinous cysts test positive). The high PPV means that if a patient's cyst fluid CEA is $\\geq 192$ ng/mL, there is an $87.5\\%$ probability that the cyst is indeed mucinous. This makes a positive test result a strong indicator for the presence of a mucinous lesion, thus providing good evidence to \"rule in\" the diagnosis and proceed with surgical resection.\n-   **Rule-out Performance**: The test has moderate sensitivity ($0.700$) and a moderate negative predictive value ($0.654$). The sensitivity of $0.700$ means the test fails to detect $30\\%$ of mucinous cysts (false negative rate). The NPV of $0.654$ indicates that if a patient has a negative test result (CEA $ 192$ ng/mL), there is still a $1 - 0.654 = 0.346$, or $34.6\\%$, chance that the lesion is actually mucinous. This level of uncertainty is too high to confidently \"rule out\" a mucinous neoplasm based on a negative test alone. Therefore, the test is not very reliable for excluding the diagnosis.\n\nIn summary, the high specificity and PPV make the CEA test at this cutoff useful for confirming (ruling in) mucinous cysts, while its moderate sensitivity and NPV limit its utility for confidently excluding (ruling out) them.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.700  0.850  0.875  0.654\n\\end{pmatrix}\n}\n$$", "id": "4613755"}, {"introduction": "In clinical practice, diagnostic certainty is often built by combining multiple pieces of evidence. While a single biomarker like $CEA$ is useful, its power can be enhanced by considering other markers, such as cyst fluid glucose. This exercise [@problem_id:5107862] challenges you to move beyond single-test evaluation by calculating a combined positive likelihood ratio ($LR^{+}$) for two independent tests, demonstrating how to quantitatively synthesize data to arrive at a more robust diagnostic conclusion.", "problem": "A $54$-year-old patient is evaluated for a pancreatic tail cyst discovered incidentally on cross-sectional imaging. Magnetic resonance cholangiopancreatography shows a non-communicating macrocystic lesion without main pancreatic duct dilation. Endoscopic ultrasound-guided fine needle aspiration yields cyst fluid carcinoembryonic antigen (CEA) of $250$ ng/mL and glucose of $25$ mg/dL. Assume that a mucinous cystic neoplasm is defined biologically by the presence of mucin-producing epithelium, and that an intraductal papillary mucinous neoplasm (IPMN) typically communicates with the pancreatic ductal system, whereas serous cystadenoma is non-mucinous. Consider two binary tests for mucinous origin using thresholds $CEA  192$ ng/mL and $glucose  50$ mg/dL. For the CEA threshold, sensitivity is $0.80$ and specificity is $0.85$. For the glucose threshold, sensitivity is $0.85$ and specificity is $0.80$. \n\nUsing only foundational definitions of sensitivity, specificity, and positive likelihood ratio, and assuming conditional independence of the two tests given the true cyst type, do the following:\n\n1. Briefly justify, based on the biological and anatomical features provided, why a mucinous origin is favored over a serous cystadenoma in this case.\n2. Compute the combined positive likelihood ratio $LR^{+}$ for the conjunction of both tests being positive in this patient. Provide the final $LR^{+}$ as an exact value (no rounding). The final answer must be a single real number without units.", "solution": "The problem statement has been critically validated and is deemed valid. It is scientifically grounded, well-posed, and objective, providing all necessary information for a complete solution.\n\nThe problem presents two tasks: first, to provide a qualitative justification for a mucinous origin of a pancreatic cyst based on provided clinical data, and second, to perform a quantitative calculation of a combined positive likelihood ratio for two diagnostic tests.\n\n**Part 1: Justification for Mucinous Origin**\n\nThe goal is to differentiate a mucinous neoplasm (such as a mucinous cystic neoplasm, MCN, or an intraductal papillary mucinous neoplasm, IPMN) from a non-mucinous one (a serous cystadenoma, SCA) based on the provided findings.\n\n1.  **Anatomical Features:** The problem describes the lesion as a \"non-communicating macrocystic lesion without main pancreatic duct dilation.\" According to the provided definitions, an IPMN \"typically communicates with the pancreatic ductal system.\" The explicit finding of a *non-communicating* cyst argues against a typical IPMN and is a classic feature of an MCN. Both MCNs and IPMNs are mucinous. Serous cystadenomas are also typically non-communicating, so this feature alone does not distinguish between MCN and SCA.\n\n2.  **Biological and Chemical Features:** The definitive distinction between mucinous and serous cysts lies in their cellular origin and the fluid they contain.\n    - A mucinous cystic neoplasm is defined by \"the presence of mucin-producing epithelium.\"\n    - A serous cystadenoma is defined as \"non-mucinous.\"\n    - The endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) provides cyst fluid for analysis, which directly probes the cyst's internal environment. The results were:\n        - Carcinoembryonic antigen (CEA) of $250$ ng/mL.\n        - Glucose of $25$ mg/dL.\n    - The problem provides two binary tests for mucinous origin based on these markers:\n        - The CEA test is positive if $CEA  192$ ng/mL. The patient's value of $250$ ng/mL is greater than this threshold, yielding a positive result.\n        - The glucose test is positive if $glucose  50$ mg/dL. The patient's value of $25$ mg/dL is less than this threshold, also yielding a positive result.\n    - Since both tests explicitly designed to identify mucinous cysts are positive, this provides strong evidence that the cyst is of mucinous origin. The high CEA level reflects secretion from the mucin-producing epithelium, and the low glucose level is thought to result from metabolic consumption by the neoplastic cells lining the cyst. These findings are inconsistent with a serous cystadenoma, which is non-mucinous and typically has very low CEA and glucose levels similar to plasma.\n\nIn summary, while the non-communicating nature of the cyst helps differentiate between subtypes of mucinous neoplasms (favoring MCN over IPMN), the most compelling evidence favoring a mucinous origin over a serous one comes from the cyst fluid chemistry. The combination of a high CEA level ($250  192$) and a low glucose level ($25  50$) is highly characteristic of a mucinous cyst and directly contradicts the expected profile of a serous cystadenoma.\n\n**Part 2: Computation of the Combined Positive Likelihood Ratio ($LR^{+}$)**\n\nLet $D$ represent the event that the cyst is of mucinous origin (the \"disease\" or condition of interest). Let $\\bar{D}$ be the event that the cyst is not of mucinous origin (e.g., serous).\nLet $T_1$ be the event of a positive CEA test, defined as $CEA  192$ ng/mL.\nLet $T_2$ be the event of a positive glucose test, defined as $glucose  50$ mg/dL.\nThe patient's test results are positive for both $T_1$ and $T_2$.\n\nThe fundamental definitions for a diagnostic test are:\n-   Sensitivity ($sens$): The probability of a positive test result given the presence of the disease, $P(T^+ | D)$.\n-   Specificity ($spec$): The probability of a negative test result given the absence of the disease, $P(T^- | \\bar{D})$.\n\nThe positive likelihood ratio ($LR^{+}$) for a single test is defined as the ratio of the probability of a positive test in a diseased individual to the probability of a positive test in a non-diseased individual.\n$$LR^{+} = \\frac{P(T^+ | D)}{P(T^+ | \\bar{D})}$$\nSince $P(T^+ | \\bar{D}) = 1 - P(T^- | \\bar{D}) = 1 - spec$, the formula becomes:\n$$LR^{+} = \\frac{sens}{1 - spec}$$\n\nThe given data for the two tests are:\n-   Test $T_1$ (CEA): $sens_1 = 0.80$, $spec_1 = 0.85$.\n-   Test $T_2$ (Glucose): $sens_2 = 0.85$, $spec_2 = 0.80$.\n\nFirst, we calculate the individual positive likelihood ratios, $LR^{+}_1$ and $LR^{+}_2$:\n$$LR^{+}_1 = \\frac{sens_1}{1 - spec_1} = \\frac{0.80}{1 - 0.85} = \\frac{0.80}{0.15}$$\n$$LR^{+}_2 = \\frac{sens_2}{1 - spec_2} = \\frac{0.85}{1 - 0.80} = \\frac{0.85}{0.20}$$\n\nWe need to compute the combined positive likelihood ratio, $LR^{+}_{\\text{comb}}$, for the event that both tests are positive ($T_1 \\cap T_2$). This is defined as:\n$$LR^{+}_{\\text{comb}} = \\frac{P(T_1 \\cap T_2 | D)}{P(T_1 \\cap T_2 | \\bar{D})}$$\n\nThe problem states to assume conditional independence of the two tests given the true cyst type. This means:\n$P(T_1 \\cap T_2 | D) = P(T_1 | D) \\times P(T_2 | D) = sens_1 \\times sens_2$\n$P(T_1 \\cap T_2 | \\bar{D}) = P(T_1 | \\bar{D}) \\times P(T_2 | \\bar{D}) = (1 - spec_1) \\times (1 - spec_2)$\n\nSubstituting these into the formula for $LR^{+}_{\\text{comb}}$:\n$$LR^{+}_{\\text{comb}} = \\frac{sens_1 \\times sens_2}{(1 - spec_1) \\times (1 - spec_2)}$$\nThis is equivalent to the product of the individual likelihood ratios:\n$$LR^{+}_{\\text{comb}} = \\left( \\frac{sens_1}{1 - spec_1} \\right) \\times \\left( \\frac{sens_2}{1 - spec_2} \\right) = LR^{+}_1 \\times LR^{+}_2$$\n\nNow, we substitute the given numerical values to find the exact value:\n$$LR^{+}_{\\text{comb}} = \\left( \\frac{0.80}{0.15} \\right) \\times \\left( \\frac{0.85}{0.20} \\right)$$\nTo compute the exact value, we convert the decimals to fractions:\n$$LR^{+}_{\\text{comb}} = \\left( \\frac{80/100}{15/100} \\right) \\times \\left( \\frac{85/100}{20/100} \\right) = \\left( \\frac{80}{15} \\right) \\times \\left( \\frac{85}{20} \\right)$$\nSimplify each fraction:\n$$\\frac{80}{15} = \\frac{16 \\times 5}{3 \\times 5} = \\frac{16}{3}$$\n$$\\frac{85}{20} = \\frac{17 \\times 5}{4 \\times 5} = \\frac{17}{4}$$\nNow, multiply the simplified fractions:\n$$LR^{+}_{\\text{comb}} = \\frac{16}{3} \\times \\frac{17}{4} = \\frac{16 \\times 17}{3 \\times 4}$$\nWe can cancel a factor of $4$ from the numerator and denominator:\n$$LR^{+}_{\\text{comb}} = \\frac{(4 \\times 4) \\times 17}{3 \\times 4} = \\frac{4 \\times 17}{3} = \\frac{68}{3}$$\n\nThe combined positive likelihood ratio for both tests being positive is $\\frac{68}{3}$.", "answer": "$$ \\boxed{\\frac{68}{3}} $$", "id": "5107862"}, {"introduction": "The culmination of diagnostic evaluation is the formulation of a management plan. For pancreatic cysts, this decision often involves weighing the risks of surgery against the risks of malignant progression, guided by established clinical frameworks. This final practice problem [@problem_id:5107863] places you in the role of the surgical decision-maker, requiring you to apply the nuanced rules of the Fukuoka and AGA guidelines to a complex patient case and justify the choice between surgery and surveillance.", "problem": "A patient is evaluated for a suspected branch-duct intraductal papillary mucinous neoplasm (IPMN) of the pancreas within a surgical decision-making context. High-quality cross-sectional imaging reports a unilocular cyst measuring $3.2\\ \\mathrm{cm}$ in the uncinate process with a mural nodule measuring $4\\ \\mathrm{mm}$, a main pancreatic duct (MPD) caliber of $6\\ \\mathrm{mm}$ without upstream ductal obstruction, and a serum Carbohydrate Antigen $19\\text{-}9$ (CA $19\\text{-}9$) concentration of $80\\ \\mathrm{U/mL}$. The patient is asymptomatic, surgically fit, and has no evidence of obstructive jaundice, lymphadenopathy, or parenchymal atrophy. Endoscopic ultrasound (EUS) has not yet been performed.\n\nUsing the following well-tested, foundational facts and definitions:\n- Intraductal Papillary Mucinous Neoplasm (IPMN) is a mucin-producing cystic neoplasm with malignant potential; branch-duct IPMN arises from secondary ducts and exhibits lower baseline malignancy risk than main-duct IPMN.\n- The Fukuoka consensus criteria classify findings as high-risk stigmata versus worrisome features. High-risk stigmata include obstructive jaundice attributable to a pancreatic head lesion, enhancing mural nodule $\\geq 5\\ \\mathrm{mm}$ or solid component, and MPD $\\geq 10\\ \\mathrm{mm}$. Worrisome features include cyst $\\geq 3\\ \\mathrm{cm}$, enhancing mural nodule $ 5\\ \\mathrm{mm}$, thickened/enhancing wall, MPD $5$–$9\\ \\mathrm{mm}$, abrupt change in duct caliber with distal atrophy, lymphadenopathy, elevated CA $19\\text{-}9$ ($ 37\\ \\mathrm{U/mL}$), and rapid growth (e.g., $\\geq 5\\ \\mathrm{mm}$ over $2$ years). Worrisome features prompt EUS, and resection is recommended when EUS demonstrates high-risk stigmata or cytology suspicious/positive for high-grade dysplasia or carcinoma.\n- The American Gastroenterological Association (AGA) framework designates three high-risk imaging features: cyst size $\\geq 3\\ \\mathrm{cm}$, presence of a solid component, and a dilated MPD. It suggests EUS with fine needle aspiration (FNA) for cysts with $\\geq 2$ high-risk features, and recommends surgical resection when there is both a solid component and a dilated duct and/or positive/suspicious cytology.\n\nWhich management approach most accurately reflects the recommendations of the Fukuoka and AGA frameworks for this patient?\n\nA. Fukuoka: immediate surgical resection; AGA: immediate surgical resection.\n\nB. Fukuoka: EUS-based risk stratification followed by surveillance unless EUS reveals high-risk stigmata or suspicious cytology; AGA: immediate surgical resection based on the coexistence of a solid component and a dilated main pancreatic duct.\n\nC. Fukuoka: noninvasive surveillance without EUS; AGA: noninvasive surveillance without EUS.\n\nD. Fukuoka: immediate surgical resection triggered by elevated CA $19\\text{-}9$; AGA: surveillance because cyst size is $ 4\\ \\mathrm{cm}$.\n\nE. Fukuoka: immediate surgical resection due to mural nodule $ 5\\ \\mathrm{mm}$; AGA: EUS with FNA and surveillance unless cytology is positive.", "solution": "The problem statement is validated as scientifically grounded, well-posed, objective, and internally consistent. It provides a specific clinical scenario and two sets of explicit guidelines (Fukuoka and AGA) for evaluation.\n\n**Derivation of Recommendation based on Fukuoka Consensus Criteria:**\n\nThe Fukuoka guidelines distinguish between \"high-risk stigmata\" (HRS), which are absolute indications for resection, and \"worrisome features\" (WF), which prompt further investigation with endoscopic ultrasound (EUS).\n\n1.  **Evaluation for High-Risk Stigmata (HRS):**\n    - Obstructive jaundice: Absent.\n    - Enhancing mural nodule $\\geq 5\\ \\mathrm{mm}$: Absent. The patient's nodule measures $4\\ \\mathrm{mm}$.\n    - Main Pancreatic Duct (MPD) caliber $\\geq 10\\ \\mathrm{mm}$: Absent. The patient's MPD is $6\\ \\mathrm{mm}$.\n    - **Conclusion:** The patient has **no** high-risk stigmata. Therefore, immediate surgical resection is not indicated under these criteria based on the initial imaging.\n\n2.  **Evaluation for Worrisome Features (WF):**\n    - Cyst size $\\geq 3\\ \\mathrm{cm}$: Present. The patient's cyst is $3.2\\ \\mathrm{cm}$.\n    - Enhancing mural nodule $ 5\\ \\mathrm{mm}$: Present. The patient's nodule is $4\\ \\mathrm{mm}$.\n    - MPD caliber $5$–$9\\ \\mathrm{mm}$: Present. The patient's MPD is $6\\ \\mathrm{mm}$.\n    - Elevated serum CA $19\\text{-}9$ ($ 37\\ \\mathrm{U/mL}$): Present. The patient's level is $80\\ \\mathrm{U/mL}$.\n    - **Conclusion:** The patient has **multiple** worrisome features.\n\n3.  **Fukuoka Management Plan:** The presence of one or more WFs mandates further risk stratification with EUS. Resection is recommended only if EUS reveals HRS or suspicious/positive cytology. Thus, the correct next step is EUS-based risk stratification.\n\n**Derivation of Recommendation based on AGA Framework:**\n\nThe AGA framework uses a set of \"high-risk imaging features\" (HRIF) to guide management.\n\n1.  **Evaluation for High-Risk Imaging Features (HRIF):**\n    - Cyst size $\\geq 3\\ \\mathrm{cm}$: Present. The patient's cyst is $3.2\\ \\mathrm{cm}$.\n    - Presence of a solid component: Present. The patient has a $4\\ \\mathrm{mm}$ mural nodule.\n    - Dilated MPD: Present. An MPD of $6\\ \\mathrm{mm}$ is considered dilated in this context.\n    - **Conclusion:** The patient has all $3$ HRIFs.\n\n2.  **AGA Management Plan:** The guidelines state: \"recommends surgical resection when there is **both a solid component and a dilated duct** and/or positive/suspicious cytology.\" The patient has both a solid component (the mural nodule) and a dilated MPD ($6\\ \\mathrm{mm}$). This combination is sufficient, on its own, to recommend immediate surgical resection.\n\n**Summary of Recommendations:**\n- **Fukuoka:** Proceed to EUS for risk stratification.\n- **AGA:** Proceed to immediate surgical resection.\n\n**Option-by-Option Analysis:**\n\n**A. Fukuoka: immediate surgical resection; AGA: immediate surgical resection.**\n- **Incorrect.** The Fukuoka recommendation is incorrect. The patient has only WFs, not HRS, so EUS is indicated before any decision on resection.\n\n**B. Fukuoka: EUS-based risk stratification followed by surveillance unless EUS reveals high-risk stigmata or suspicious cytology; AGA: immediate surgical resection based on the coexistence of a solid component and a dilated main pancreatic duct.**\n- **Correct.** This option accurately reflects the derived management plans for both frameworks. The Fukuoka recommendation correctly identifies the role of EUS in response to WFs. The AGA recommendation correctly identifies that the combination of a solid component and a dilated duct is a direct indication for surgery.\n\n**C. Fukuoka: noninvasive surveillance without EUS; AGA: noninvasive surveillance without EUS.**\n- **Incorrect.** Both recommendations are incorrect. The presence of multiple WFs (Fukuoka) and HRIFs (AGA) precludes simple surveillance without further investigation or intervention.\n\n**D. Fukuoka: immediate surgical resection triggered by elevated CA $19\\text{-}9$; AGA: surveillance because cyst size is $ 4\\ \\mathrm{cm}$.**\n- **Incorrect.** The Fukuoka recommendation is wrong; elevated CA $19\\text{-}9$ is a WF, not an HRS. The AGA recommendation is wrong; the size threshold is $\\geq 3\\ \\mathrm{cm}$ (which the patient meets), not $4\\ \\mathrm{cm}$, and other features mandate resection.\n\n**E. Fukuoka: immediate surgical resection due to mural nodule $ 5\\ \\mathrm{mm}$; AGA: EUS with FNA and surveillance unless cytology is positive.**\n- **Incorrect.** The Fukuoka recommendation is wrong; a nodule $ 5\\ \\mathrm{mm}$ is a WF, which prompts EUS, not immediate resection. The AGA recommendation is incomplete; while EUS is an option, the guidelines more strongly recommend resection based on the specific combination of imaging findings present.", "answer": "$$\\boxed{B}$$", "id": "5107863"}]}